1. Home
  2. NRC vs CTNM Comparison

NRC vs CTNM Comparison

Compare NRC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Research Corporation (Delaware)

NRC

National Research Corporation (Delaware)

HOLD

Current Price

$14.06

Market Cap

428.2M

Sector

Health Care

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$15.16

Market Cap

575.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRC
CTNM
Founded
1981
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
428.2M
575.3M
IPO Year
1997
2024

Fundamental Metrics

Financial Performance
Metric
NRC
CTNM
Price
$14.06
$15.16
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$18.60
AVG Volume (30 Days)
128.2K
175.1K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
4.62%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$119,686,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.58
N/A
Revenue Growth
1.81
N/A
52 Week Low
$9.76
$3.35
52 Week High
$22.79
$16.33

Technical Indicators

Market Signals
Indicator
NRC
CTNM
Relative Strength Index (RSI) 43.33 57.91
Support Level $11.59 $10.17
Resistance Level $14.20 $16.01
Average True Range (ATR) 1.00 0.86
MACD 0.18 -0.12
Stochastic Oscillator 60.99 58.67

Price Performance

Historical Comparison
NRC
CTNM

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: